Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate for diabetic retinopathy in adults with type 1 diabetes
ACTRN12611000249954Phase 3Active, not recruiting
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate in diabetic retinopathy (DR), diabetic glomerulosclerosis and diabetes mellitus type 1 (T1D) (3 arms), sponsored by NHMRC Clinical Trials Centre. Primary endpoint: Clinically significant retinopathy progression. Started Nov 2016; status: active, not recruiting.
02
Drugs
fenofibrate
03
Conditions
diabetic retinopathy (DR)diabetic glomerulosclerosisdiabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12611000249954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000249954.